Novo Nordisk A/S (NVO): Among the Cheap Pharmaceutical Stocks to Buy According to Analysts
We recently compiled a list of the 10 Cheap Pharmaceutical Stocks to Buy According to Analysts. In this article, we are going ...
This Is the Best-Performing Vanguard ETF So Far in 2025. Is It a No-Brainer Buy?
However, the Vanguard S&P 500 Growth ETF isn't the best performer in the Vanguard family so far in 2025. Instead, it's an ETF ...
devdiscourse9h
Health Sector Shifts: From Drug Approvals to Supply Disruptions
The current state of health services highlights crucial sectors facing disruptions and developments, from US foreign aid freezes affecting disease control supply chains, to the FDA's actions on new ...
Make-or-break plan to seal oil giant BP's fate
Auchincloss has pledged a root-and-branch overhaul of BP's strategy. The company is in crisis after it revealed profits ...
Lilly, Novo dominance to continue as TD Cowen lifts 2030 GLP-1 sales forecast by 38%
TD Cowen projects that with Eli Lilly (NYSE:LLY) and Novo Nordisk (NVO) continuing their dominance, global sales of the GLP-1 class of weight loss/obesity drugs could reach $139B by 2030, indicating ...
FDA announces end to Wegovy and Ozempic drug shortages, but it could mean higher prices
The FDA has announced that the shortage of Wegovy and Ozempic, medications used for weight loss and diabetes management, is ...
Novo’s Weight Loss Drugs Removed from FDA Shortage List
The U.S. Food and Drug Administration said on Friday there was no longer a shortage of Novo Nordisk’s popular weight-loss and ...
The Independent Singapore23h
Singapore biotech tycoon Huang Zhenhua’s assets frozen in US$830 million legal battle with pharma giant
SINGAPORE: Pharmaceutical giant Novo Nordisk is taking legal action in a Singapore court, seeking damages of up to US$830 ...